Following the 2022 approval of the antibody-drug conjugate fam-trastuzumab deruxtecan (T-DXd), the therapeutic landscape of HER2-mutant NSCLC further expanded in 2025 with the regulatory approval of two highly selective oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.